ABL Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$126.56 |
| 52 Week High | US$128.60 |
| 52 Week Low | US$91.68 |
| Beta | 0.74 |
| 1 Month Change | 8.71% |
| 3 Month Change | 12.76% |
| 1 Year Change | 14.35% |
| 3 Year Change | 15.79% |
| 5 Year Change | 84.38% |
| Change since IPO | 257.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -2.4% | -0.6% |
| 1Y | 14.3% | -4.7% | 14.8% |
Return vs Industry: ABL exceeded the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: ABL matched the German Market which returned 14.8% over the past year.
Price Volatility
| ABL volatility | |
|---|---|
| ABL Average Weekly Movement | 2.5% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: ABL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ABL's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABL fundamental statistics | |
|---|---|
| Market cap | €223.69b |
| Earnings (TTM) | €12.81b |
| Revenue (TTM) | €40.10b |
17.5x
P/E Ratio5.6x
P/S RatioIs ABL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABL income statement (TTM) | |
|---|---|
| Revenue | US$41.95b |
| Cost of Revenue | US$18.58b |
| Gross Profit | US$23.37b |
| Other Expenses | US$9.97b |
| Earnings | US$13.40b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.73 |
| Gross Margin | 55.71% |
| Net Profit Margin | 31.95% |
| Debt/Equity Ratio | 37.6% |
How did ABL perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 23:04 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 59 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Stephan Gasteyger | Atlantic Equities LLP |
| Ishan Majumdar | Baptista Research |